Abstract
A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have